Chi Advisors LLC Ikena Oncology, Inc. Transaction History

Chi Advisors LLC

$203 Million
Q3 2023

A detailed history of Chi Advisors LLC transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Chi Advisors LLC holds 2,180,934 shares of IKNA stock, worth $3.69 Million. This represents 4.65% of its overall portfolio holdings.

Number of Shares

2,180,934

Previous 2,122,040 2.78%

Holding current value

$3.69 Million

Previous $13.9 Million 32.16%

% of portfolio

4.65%

Previous 5.23%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$4.09 - $6.43 $240,876 - $378,688	58,894 Added 2.78%	2,180,934 $9.44 Million
Q2 2023 Aug 11, 2023	BUY	$3.5 - $7.31 $1.61 Million - $3.37 Million	461,168 Added 27.77%	2,122,040 $13.9 Million
Q1 2023 May 11, 2023	BUY	$2.62 - $4.97 $61,570 - $116,795	23,500 Added 1.44%	1,660,872 $5.73 Million
Q4 2022 Feb 13, 2023	BUY	$2.0 - $3.7 $846,136 - $1.57 Million	423,068 Added 34.84%	1,637,372 $4.36 Million
Q3 2022 Nov 09, 2022	BUY	$3.46 - $6.0 $426,849 - $740,202	123,367 Added 11.31%	1,214,304 $4.31 Million
Q2 2022 Aug 12, 2022	BUY	$3.23 - $7.4 $892,067 - $2.04 Million	276,182 Added 33.9%	1,090,937 $4.83 Million
Q1 2022 May 16, 2022	SELL	$5.61 - $13.85 $5 - $13	-1 Reduced -0.0%	814,755 $4.97 Million
Q4 2021 Feb 11, 2022	BUY	$10.52 - $16.96 $5.26 Million - $8.48 Million	499,756 Added 158.65%	814,756 $10.2 Million
Q3 2021 Nov 15, 2021	SELL	$9.82 - $15.23 $4.91 Million - $7.61 Million	-499,756 Reduced 61.34%	315,000 $3.98 Million
Q1 2021 May 14, 2021	BUY	$25.6 - $32.0 $20.9 Million - $26.1 Million	814,756 New	814,756 $23 Million

Others Institutions Holding IKNA

# of Institutions

Shares Held

30.6M

Call Options Held

Put Options Held

View Full List

About Ikena Oncology, Inc.

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $61.3M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

More about IKNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Chi Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chi Advisors LLC with notifications on news.

Account